fda compounding semaglutide enforcement november 2025 news GLP-1 Weight Loss Drug in 2025: State Attorneys General Step into a Growing Regulatory Gap Drugmakers battle pharmacies over compounded

Description

GLP-1 microdosing uses sub-therapeutic doses (0.05-0.25mg semaglutide weekly vs standard 0.25-2.4mg) to minimize gastrointestinal side effects while achieving mild appetite suppression

If your medication has frozen and thawed, it must be discarded, even if it looks clear

FDA described it as approved 50 days after filing under the Commissioners National Priority Voucher pilot programan unusually fast NME approval

Note that Lilly described this transition from tirzepatide to orforglipron as ATTAIN-MANTAIN, somewhat signalling they embrace the induction-maintenance model

Review MadeMed's current program options and pricing here What MadeMed Actually Offers: A Verified Category-by-Category Breakdown MadeMed's published website covers four treatment categories